Curcumin incorporated titanium dioxide nanoparticles as MRI contrasting agent for early diagnosis of atherosclerosis- rat model

MRI is an excellent diagnostic technique for atherosclerosis in a non-invasive manner. Application of contrasting agents can improve its contrast through ionic properties. Macrophages and foam cells produce MCP-1 antibody, the sign of development of atherosclerosis. The work aims to develop novel curcumin incorporated titanium dioxide nanoparticles (CTNPs) conjugated with MCP-1 antibody with the specific targeting capability to macrophage-foam cells as contrasting agent for MRI. In vivo toxicity studies of Curcumin, TNPs and CTNPs were also done in Sprague dawley rats by GGT and ALP assays and found to be normal in comparison with control. Histopathology of aorta confirmed that the compound could not elicit a toxic effect in the target organ. Rats were fed with a high cholesterol diet to develop atherosclerotic foam cells and confirmed by Sudan IV staining and serum cholesterol level. CTNP-MCP-1 was injected into animals through tail vein and MRI scanning was done, gave contrasting images of atherosclerotic aorta in comparison with normal. Thus CTNPs can be used as a cost-effective contrasting tool for diagnosis of atherosclerosis at early stages in view of clinical imaging.